Ziconotide is a synthetic, 25-amino acid peptide analog of ω-conotoxin MVIIA, a neurotoxic peptide originally isolated from the venom of the predatory marine cone snail Conus magus. Its discovery stemmed from research into the potent paralytic effects of cone snail venoms on fish, which led to the identification of a family of peptides (conotoxins) that selectively block specific ion channels in the nervous system. Ziconotide represents a significant milestone in both peptide pharmacology and pain management, as it was the first and remains the only intrathecally administered, non-opioid, N-type calcium channel blocker approved for clinical use. Its development highlighted the potential of marine natural products as sources for novel therapeutic agents with highly specific mechanisms of action.
Ziconotide is a cornerstone peptide in neuropharmacology due to its highly selective mechanism and its role in treating severe, chronic pain that is refractory to other therapies, including systemic opioids. Its significance extends beyond its clinical application, as it has become an invaluable research tool for studying N-type voltage-sensitive calcium channels (VSCCs) and their critical role in neurotransmitter release, particularly in nociceptive pathways within the spinal cord. The peptide’s inability to cross the blood-brain barrier necessitates direct intrathecal administration, which underscores its localized site of action and differentiates its therapeutic profile from systemically administered analgesics.
Quick Facts
| Also Known As | SNX-111, Prialt, ω-Conotoxin MVIIA |
|---|---|
| Sequence | CKGKGAKCSRLMYDCCTGSCRSGKC |
| Molecular Formula | C102H172N36O32S7 |
| Molecular Weight | 2639.2 Da |
| PubChem CID | 16135415 |
Research Parameters
| Half-Life | ~4.6 hours in human cerebrospinal fluid (CSF) following intrathecal administration |
|---|---|
| Stability | Lyophilized powder is stable when stored as directed. After reconstitution in preservative-free sterile saline or according to manufacturer instructions, solutions for intrathecal infusion are typically stable for up to 60 days at 4°C in an implanted pump reservoir, though specific stability data depends on formulation and pump model. |
| Solubility | Preservative-free 0.9% Sodium Chloride Injection (Sterile Saline) |
| Storage (Lyophilized) | -20°C or below, protect from light and moisture |
| Storage (Reconstituted) | For research: 2-8°C (refrigerated) for short-term studies. For clinical infusion pumps: stable at body temperature (37°C) within the pump for specified durations (e.g., 60 days). |
| Typical Research Dose | Clinical research: 2.4 to 19.2 mcg/day via continuous intrathecal infusion. Preclinical research: 1-10 ng per intrathecal bolus in rodents. |
| Cycle Parameters | Continuous, long-term administration via implanted intrathecal pump. In research protocols, treatment is ongoing with dose titration over weeks to months until an effective and tolerable maintenance dose is established. |
| Amino Acid Count | 25 |
Mechanism of Action
Ziconotide is a selective and potent blocker of N-type (Cav2.2) voltage-sensitive calcium channels (VSCCs). These channels are predominantly located on presynaptic terminals of primary afferent neurons in the dorsal horn of the spinal cord. By binding to these channels with high affinity, ziconotide inhibits the influx of calcium ions that is required for the release of pro-nociceptive neurotransmitters, such as substance P, glutamate, and calcitonin gene-related peptide (CGRP), from the central terminals of primary sensory neurons.
Primary Pathway - N-type Calcium Channel Blockade: Ziconotide binds with high affinity and selectivity to the α1B subunit of the neuronal N-type (Cav2.2) voltage-gated calcium channel. This binding is state-dependent, with higher affinity for the channel's open or inactivated states. The physical blockade of the channel pore prevents calcium ion influx.
Inhibition of Neurotransmitter Release: The reduction in presynaptic calcium influx directly and potently inhibits the calcium-dependent exocytosis of vesicles containing neurotransmitters and neuromodulators from nociceptive primary afferent terminals. This occurs specifically in the superficial laminae of the spinal cord dorsal horn.
Modulation of Pain Signaling: By suppressing the release of key excitatory neurotransmitters involved in pain transmission (e.g., substance P, glutamate), ziconotide attenuates the synaptic activation of second-order projection neurons in the spinal cord. This effectively interrupts the relay of nociceptive signals to higher brain centers, producing analgesia without activating opioid receptors.
Research Applications
Chronic Pain Research: Ziconotide is a premier research tool for investigating the pathophysiology of severe neuropathic and inflammatory pain states. Studies utilize it to dissect the specific contribution of N-type calcium channels and presynaptic neurotransmitter release in animal models of nerve injury, chemotherapy-induced neuropathy, and postoperative pain. Its efficacy in intractable pain conditions provides a benchmark for evaluating novel non-opioid analgesic targets.
Neuropharmacology and Channel Biology: The peptide is extensively used in basic science to study the structure, function, and distribution of N-type calcium channels. Research focuses on its binding site, which has helped map channel domains and understand gating mechanisms. It is also employed to investigate the role of these channels in processes beyond nociception, such as sympathetic outflow and certain motor functions.
Drug Delivery and Formulation Science: Due to its requirement for intrathecal delivery, ziconotide serves as a model compound in research focused on advanced drug delivery systems for the central nervous system. Studies explore sustained-release formulations, implantable pumps, and methods to improve peptide stability in cerebrospinal fluid to enhance therapeutic windows and reduce dosing frequency.
Safety & Side Effects
The safety profile from clinical trials and post-marketing surveillance is characterized by a narrow therapeutic window and significant neuropsychiatric and neurological side effects, which are often dose-dependent and related to rapid titration. Common reported adverse effects include dizziness, nausea, nystagmus, confusion, headache, and somnolence. More serious effects can include psychiatric symptoms such as hallucinations, suicidal ideation, and cognitive impairment, as well as meningitis (related to the delivery system). In animal toxicity studies, high doses cause motor impairment and ataxia. Theoretical concerns from research include the potential for effects on sympathetic nervous system function due to N-channel blockade in autonomic pathways. Anecdotal reports from clinical use strongly emphasize that improper dosing or rapid escalation leads to severe adverse events.
Dosage Information
This information is derived from published clinical and preclinical research literature and is presented for educational purposes only. Ziconotide is not for personal use.
In clinical research for severe chronic pain, ziconotide is administered exclusively via continuous intrathecal infusion using a programmable implanted pump. The dosing is highly individualized and initiated at very low doses to mitigate adverse effects. A typical research/clinical starting dose is 0.1 mcg/hour (2.4 mcg/day). The dose is then slowly titrated upward based on analgesic response and tolerability, with common maximum doses in studies ranging from 0.5 to 0.8 mcg/hour (12 to 19.2 mcg/day). In animal research (e.g., rodent models), doses are given via single intrathecal bolus injections and are typically in the range of 1 to 10 ng (nanograms) per animal, or calculated based on ng/kg, to study acute analgesic effects and mechanisms.
References
Miljanich, G.P. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Current Medicinal Chemistry, 2004.
McGivern, J.G. Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatric Disease and Treatment, 2007.
Atanassoff, P.G., et al. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Regional Anesthesia and Pain Medicine, 2000.
Staats, P.S., et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA, 2004.
Olivera, B.M., et al. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. Biochemistry, 1987.
Wang, Y.X., et al. Antinociceptive properties of ziconotide, a selective blocker of N-type neuronal calcium channels. Journal of Pharmacology and Experimental Therapeutics, 2000.
Rauck, R.L., et al. Long-term intrathecal ziconotide therapy: a case series and review of the literature. Pain Medicine, 2009.